

Dr Russell Basser appointed as non-executive director

Melbourne, Australia; 31 January 2023: The Board of **Starpharma Holdings Limited** (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.

Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.

Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.

As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation.

Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines.

Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now *Cancer Trials Australia*) for seven years.

Starpharma Chairman, Mr Rob Thomas said: "We are pleased to welcome Dr Basser to Starpharma's Board, especially at such an exciting time for the Company. Dr Basser has extensive clinical development experience across multiple therapeutic areas, including oncology and influenza vaccines. His combined and very broad medical and corporate expertise, from a 30-plus year career in the medical and biopharmaceutical industry, will add to the breadth of capability and experience of Starpharma's Board."

Dr Basser said: "Starpharma has developed an impressive portfolio of products across oncology and infectious diseases, as well as commercial partnerships with global companies, based on its dendrimer technology. I am pleased to join the Company at such a dynamic stage and look forward to contributing to Starpharma's ongoing development and to bringing improved medical products to patients in need."

Dr Basser is a qualified physician, having completed a Bachelor of Medicine and Bachelor of Surgery and a Doctor of Medicine at the University of Melbourne. He is a Fellow of The Royal Australasian College of Physicians and an author of more than 90 peer-reviewed papers, reviews, and book chapters.

Dr Basser has previously served on the Board of the ANZ Breast Cancer Trials Group and advised on its Scientific Advisory Board; and the Breast, Bowel and Lung Cancer Advisory Committees of the Anti-Cancer Council of Victoria.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for DEP[®] drug delivery, respiratory viruses and VivaGel[®].

Starpharma's proprietary drug delivery platform technology, DEP[®], is being used to improve pharmaceuticals to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP[®] versions of existing drugs, particularly in the area of anti-cancer therapies.

Starpharma's DEP[®] partnerships include oncology programs with AstraZeneca; with MSD in the area of Antibody Drug Conjugates (ADCs); with Chase Sun in the area of anti-infectives; and with other world leading pharmaceutical companies. Partnered DEP[®] programs have the potential to generate significant future milestones and royalties.

Starpharma has developed VIRALEZE[™], an antiviral nasal spray that is registered in a number of countries, including in Europe and the UK. VIRALEZE[™] is not approved for use or supply in Australia. SPL7013 is also utilised in the following products: VivaGel[®] condom and VivaGel[®] BV. VivaGel[®] products have been licensed in >160 countries and are registered in >45 countries, including in the UK, in Europe, Japan, in Southeast Asia, South Africa, Australia, and New Zealand.

Starpharma.com | [Twitter](https://twitter.com/Starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

Media: Sumit Media

Grant Titmus

Mob: +61 419 388 161

grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

4-6 Southampton Crescent

Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.